Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.

被引：3
|
作者：
Goff, L. W.
Cohen, R. B.
Berlin, J.
Noberasco, C.
Borghaei, H.
Gallo-Stampino, C.
Wang, E.
Lowe, D. Hu
Levin, W. J.
De Braud, F. G.
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] European Inst Oncol, Milan, Italy
[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[6] Pfizer Oncol, Milan, Italy
[7] Pfizer Oncol, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3009
引用
收藏
页数：1
相关论文
共 45 条
  • [1] Phase I study of PF-03446962, a fully human mab against ALK 1, a TGFβ receptor involved in tumor angiogenesis.
    Goff, L. W.
    De Braud, F. G.
    Cohen, R. B.
    Berlin, J.
    Noberasco, C.
    Borghaei, H.
    Wang, E.
    Lowe, D. Hu
    Levin, W. J.
    Gallo-Stampino, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] PHASE 1 STUDY OF PF-03446962, A HUMAN MAB AGAINST ACTIVIN RECEPTOR LIKE KINASE 1 (ALK 1), INVOLVED IN TUMOR ANGIOGENESIS
    Noberasco, C.
    Cohen, R.
    Berlin, J.
    de Braud, F.
    Borghaei, H. M. D.
    Stampino, C. Gallo
    Wang, E.
    Hu-Lowe, D.
    Levin, W. J.
    Abbattista, A.
    Goff, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [3] Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis
    Goff, Laura Williams
    Borghaei, Hossein
    Cohen, Roger B.
    Berlin, Jordan
    Noberasco, Cristina
    Stampino, Corrado Gallo
    Wang, Erjian
    Williams, James Andrew
    English, Patricia A.
    De Braud, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacoulynamics (PD)
    Lee, Kyung-Hun
    Doi, Toshihiko
    Kim, Tae Min
    Ohtsu, Atsushi
    Kim, Tae Yong
    Ikeda, Masafumi
    Yoh, Kiyotaka
    Gallo-Stampino, Corrado
    Hirohashi, Tomoko
    Suzuki, Akiyuki
    Yosuke, Fujii
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC)
    Simonelli, Matteo
    Zucali, Paolo A.
    Thomas, Melanie B.
    Brisendine, Alan
    Berlin, Jordan
    Noberasco, Cristina
    Denlinger, Crystal Shereen
    Kim, Tae-You
    Santoro, Armando
    Gallo-Stampino, Corrado
    Carpentieri, Marina
    Wang, Erjian
    Williams, James Andrew
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinomaaEuro
    Simonelli, M.
    Zucali, P.
    Santoro, A.
    Thomas, M. B.
    de Braud, F. G.
    Borghaei, H.
    Berlin, J.
    Denlinger, C. S.
    Noberasco, C.
    Rimassa, L.
    Kim, T. -Y.
    English, P. A.
    Abbattista, A.
    Stampino, C. Gallo
    Carpentieri, M.
    Williams, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1782 - 1787
  • [7] Anti-angiogenesis through inhibition of ALK-1 (activin-like receptor kinase 1) with a fully human monoclonal antibody PF-03446962
    Hu-Lowe, Dana
    Wickman, Grant
    Jiang, Xin
    Kraynov, Eugenia
    Wang, Jianying
    Amundson, Karin
    Simmons, Brett
    Liang, Shile
    Chen, Enhong
    Karlicek, Shannon
    Thompson, Jim
    Swanson, Terri
    Yan, Zhengming
    Li, Gary
    Los, Gerrit
    Hostomsky, Zdenek
    Casperson, Gerald
    Bender, Steve
    North, Michael
    CANCER RESEARCH, 2009, 69
  • [8] Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control.
    Simonelli, Matteo
    Denlinger, Crystal Shereen
    Goff, Laura Williams
    Noberasco, Cristina
    Kim, Tae-You
    Thomas, Melanie B.
    De Braud, Filippo G.
    Zucali, Paolo A.
    Santoro, Armando
    English, Patricia A.
    Gallo-Stampino, Corrado
    Wang, Erjian
    Carpentieri, Marina
    Williams, James Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
    Goff, Laura W.
    Cohen, Roger B.
    Berlin, Jordan D.
    de Braud, Filippo G.
    Lyshchik, Andrej
    Noberasco, Cristina
    Bertolini, Francesco
    Carpentieri, Marina
    Stampino, Corrado Gallo
    Abbattista, Antonello
    Wang, Erjan
    Borghaei, Hossein
    CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2146 - 2154
  • [10] PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
    A. Necchi
    P. Giannatempo
    L. Mariani
    E. Farè
    D. Raggi
    M. Pennati
    N. Zaffaroni
    F. Crippa
    A. Marchianò
    N. Nicolai
    M. Maffezzini
    E. Togliardi
    M. G. Daidone
    A. M. Gianni
    R. Salvioni
    F. De Braud
    Investigational New Drugs, 2014, 32 : 555 - 560
12345